Paris-region hospital purchasing network specializing in public procurement of health innovation (PPI/PCP) and value-based tendering.
GIP RESAH is the public hospital purchasing network for the Île-de-France region (greater Paris), specializing in group procurement for healthcare institutions. In H2020 projects, they bring real-world demand-side expertise — helping define what hospitals actually need and how to procure innovative health solutions through public procurement instruments like PPI and PCP. They act as the bridge between healthcare innovation developers and the public buyers who must adopt those innovations within complex regulatory and tendering frameworks.
EURIPHI focused directly on PPI and PCP for health innovation; inDemand on demand-driven co-creation for public entities; PROEIPAHA on promoting the European Innovation Partnership on Active and Healthy Ageing.
EURIPHI explicitly addresses MEAT (most economically advantageous tendering) and value-based healthcare procurement.
RELIEF (€1.4M, their largest project) focused on pain self-management using ICT tools, where RESAH contributed the demand/procurement perspective.
EURIPHI addressed European-wide procurement of health innovation, including cross-border healthcare dimensions.
RESAH's early H2020 involvement (2015–2017) centred on broad support activities for active and healthy ageing and demand-driven co-creation — relatively general coordination and support actions. By 2019, their focus sharpened significantly toward specific procurement instruments (PPI, PCP), value-based healthcare tendering, and cross-border health procurement, reflecting a clear maturation from general innovation support to specialized procurement expertise. The RELIEF project (2016–2021) sits in between, showing their willingness to engage deeply with specific clinical domains (pain management) as a demand-side partner.
RESAH is moving toward becoming a specialist in cross-border, value-based health procurement — a niche that will be increasingly important as EU joint purchasing and health technology assessment frameworks expand.
RESAH participates exclusively as a partner, never as coordinator — consistent with their role as a demand-side public buyer contributing real procurement needs rather than driving research agendas. Across 4 projects they worked with 56 unique partners in 12 countries, indicating they operate in large, diverse consortia typical of health innovation actions. They bring the "buyer's voice" to projects, making them a valuable but non-leading consortium member.
RESAH has collaborated with 56 unique partners across 12 countries, reflecting the broad European consortia typical of health procurement and innovation projects. Their network likely spans hospitals, procurement bodies, health technology developers, and public health organizations across Western and Southern Europe.
RESAH represents something rare in EU project consortia: the actual public buyer. While many projects include researchers, technology developers, and consultants, RESAH brings the perspective of the organization that writes the tenders and signs the purchase orders for hospitals in one of Europe's largest metropolitan areas. For any health innovation project that needs to demonstrate a credible path to public procurement, RESAH offers direct access to real demand and real tendering processes.
